Teresa Brophy Bair Net Worth

The estimated Net Worth of Teresa Brophy Bair is at least $140 Tisíc dollars as of 20 May 2024. Ms Bair owns over 2,615 units of Athenex Inc stock worth over $13,796 and over the last 4 years she sold ATNX stock worth over $126,428.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms Bair ATNX stock SEC Form 4 insiders trading

Ms has made over 3 trades of the Athenex Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently she sold 2,615 units of ATNX stock worth $57,922 on 20 May 2024.

The largest trade she's ever made was selling 2,615 units of Athenex Inc stock on 20 May 2024 worth over $57,922. On average, Ms trades about 752 units every 61 days since 2020. As of 20 May 2024 she still owns at least 68,979 units of Athenex Inc stock.

You can see the complete history of Ms Bair stock trades at the bottom of the page.

Ms. Teresa Brophy Bair biography

Teresa Brophy Bair is the Gen. Counsel, Sr. VP of Admin. & Corp. Sec. at Athenex Inc.

What's Ms Bair's mailing address?

Teresa's mailing address filed with the SEC is C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO, CA, 92130.

Insiders trading at Athenex Inc

Over the last 7 years, insiders at Athenex Inc have traded over $33,215,399 worth of Athenex Inc stock and bought 5,920,005 units worth $73,651,360 . The most active insiders traders include Advisors Llcperceptive Life..., Song Yi Zhang a Song Yi Mandra Medical Ltd .... On average, Athenex Inc executives and independent directors trade stock every 12 days with the average trade being worth of $10,843. The most recent stock trade was executed by Joe Annoni on 22 February 2023, trading 625 units of ATNX stock currently worth $125.

What does Athenex Inc do?

athenex is a global specialty oncology pharmaceutical company focused on the development and commercialization of next generation therapies for cancer diseases and supportive therapies. the company is dedicated to delivering innovative drugs that can have a life-changing impact on cancer patients. our business includes medical technology innovation centers and a unique manufacturing supply chain across both china and north america. through the connected innovation and manufacturing supply chain presence, we can identify, develop and deliver proprietary medical technology across continents and multiple regulatory environments.

Complete history of Ms Bair stock trades at Athenex Inc a Kura Oncology Inc

Athenex Inc executives and stock owners

Athenex Inc executives and other stock owners filed with the SEC include:

• Johnson Lau,
  Chief Executive Officer and Chairman of the Board
• Rudolf Kwan,
  Chief Medical Officer
• Jeffrey Yordon,
  Chief Operating Officer and President, Athenex Pharmaceutical Division
• Randoll Sze,
  Chief Financial Officer
• Simon Pedder,
  Chief Business and Strategy Officer - Proprietary Products
• Jeffrey M. Yordon,
  COO & Pres of Athenex Pharmaceutical Division
• Dr. Rudolf Kwan M.D., M.B., B.S.,
  Chief Medical Officer
• Dr. Yiu-Nam Lau M.B.B.S., M.D., F.R.C.P., Ph.D.,
  Chairman & CEO
• Benson Tsang,
  Independent Director
• Stephanie Davis,
  Independent Director
• Kim Campbell,
  Lead Independent Director
• Jinn Wu,
  Independent Director
• Jordan Kanfer,
  Independent Director
• John Vierling,
  Independent Director
• Manson Fok,
  Director
• Robert Spiegel,
  Director
• Daniel Lang,
  Senior Director - Corporate Development, President - Axis Therapeutics Limited
• Tim McCarthy,
  IR Contact Officer
• William Zuo,
  President, China Division
• Dr. Wing-Kai Chan,
  Deputy Chief Medical Officer of Orascovery & Src Kinase Platforms
• John W. Matthei,
  VP of HR
• Caileigh Dougherty,
  Director of Investor Relations
• Michael Smolinski Ph.D.,
  Chief Scientific Officer
• Steven J. Adams,
  Interim Chief Accounting Officer
• Daniel Lang M.D.,
  Sr. Director of Corp. Devel.
• Jacqueline Li,
  Director of Corp. Devel. & Investor Relations
• Steven Rubis,
  Sr. Director of Investor Relations
• Teresa Brophy Bair,
  Gen. Counsel, Sr. VP of Admin. & Corp. Sec.
• Dr. Allen Barnett,
  Co-Founder & Pres Emeritus
• James Zukin,
  
• Michael D Cannon,
  
• J Nick Riehle,
  Chief Financial Officer
• Antony Leung,
  
• Song Yi Zhang,
  Director
• John Koh,
  Director
• Advisors Llcperceptive Life...,
  
• Sheldon Trainor Degirolamo,
  Director
• Timothy De Vere Cook,
  See Remarks
• Teresa Brophy Bair,
  General Counsel, SVP Admin.
• Joe Annoni,
  Chief Financial Officer
• Steven J. Adams,
  Interim Chief Acct Officer
• Michael Smolinski,
  Chief Scientific Officer